A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naïve versus -experienced patients

Supplementary Figure 1. The transition of eczema area and severity index (EASI) on four anatomical sites in patients with atopic dermatitis treated with tralokinumab. EASI scores on head and neck, trunk, upper limbs, or lower limbs are shown as means of systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. All indices from week 4 through week 48 were significantly lower than baseline values in each group (p < 0.01 by repeated-measures ANOVA with Bonferroni correction). *p < 0.05, **p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Student’s t-test. Supplementary Figure 2. Achievement rates of eczema area and severity index (EASI) 50, EASI 75, EASI 90, EASI 100, and investigator’s global assessment (IGA) 0/1 in patients with atopic dermatitis treated with tralokinumab. Data are shown as percentages for systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. *p < 0.05, **p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Fisher’s exact test. Supplementary Figure 3. Achievement rates of peak pruritus numerical rating scale (PP-NRS) 4 and atopic dermatitis control tool (ADCT) 7 in patients with atopic dermatitis treated with tralokinumab. Data are shown as percentages for systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. *p < 0.05, **p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Fisher’s exact test. Supplementary Figure 4. The transition of laboratory indexes in patients with atopic dermatitis treated with tralokinumab. Serum IgE, thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) are shown as medians for systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. *p < 0.05, ** p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Mann–Whitney U test. Friedman's test with Bonferroni’ s correction detected significant differences from baseline values at following time-periods in each group: 1. IgE: weeks 12–48 (p < 0.01) in systemic therapy–naïve group and week 4 (p < 0.05) and weeks 12–48 (p < 0.01) in systemic therapy–experienced group. 2. TARC: weeks 4–48 (p < 0.01) in both groups. 3. LDH: week 24 (p < 0.05) and weeks 36 and 48 (p < 0.01) in systemic therapy-naïve group and weeks 4, 12 and 24 (p < 0.01), week 36 (p < 0.05) and week 48 (p < 0.01) in systemic therapy–experienced group. 4. TEC: no significant differences in either group补充图1。特罗卢单抗（tralokinumab）治疗的特应性皮炎患者4个解剖部位的湿疹面积与严重程度指数（Eczema Area and Severity Index, EASI）变化趋势。结果展示了未接受过系统治疗患者（n=92，绿色组）与接受过系统治疗患者（n=84，紫色组）在48周治疗期间头颈部、躯干、上肢或下肢的EASI评分均值。两组第4周至第48周的所有指标均显著低于基线值（采用结合Bonferroni校正的重复测量方差分析，p<0.01）。采用Student t检验，在每个时间点*p<0.05、**p<0.01表示与接受过系统治疗患者的对应值存在显著差异。 补充图2。特罗卢单抗治疗的特应性皮炎患者达到EASI 50、EASI 75、EASI 90、EASI 100以及研究者整体评分0/1（Investigator’s Global Assessment 0/1, IGA 0/1）的达标率。结果以百分比展示未接受过系统治疗患者（n=92，绿色组）与接受过系统治疗患者（n=84，紫色组）在48周治疗期间的达标情况。采用Fisher确切概率法，在每个时间点*p<0.05、**p<0.01表示与接受过系统治疗患者的对应值存在显著差异。 补充图3。特罗卢单抗治疗的特应性皮炎患者达到峰值瘙痒数字评定量表4分（Peak Pruritus Numerical Rating Scale 4, PP-NRS 4）以及特应性皮炎控制工具7分（Atopic Dermatitis Control Tool 7, ADCT 7）的达标率。结果以百分比展示未接受过系统治疗患者（n=92，绿色组）与接受过系统治疗患者（n=84，紫色组）在48周治疗期间的达标情况。采用Fisher确切概率法，在每个时间点*p<0.05、**p<0.01表示与接受过系统治疗患者的对应值存在显著差异。 补充图4。特罗卢单抗治疗的特应性皮炎患者实验室指标变化趋势。结果以中位数展示未接受过系统治疗患者（n=92，绿色组）与接受过系统治疗患者（n=84，紫色组）在48周治疗期间的血清免疫球蛋白E（Serum IgE）、胸腺活化调节趋化因子（Thymus and Activation-Regulated Chemokine, TARC）、乳酸脱氢酶（Lactate Dehydrogenase, LDH）以及嗜酸性粒细胞总数（Total Eosinophil Count, TEC）。 *p<0.05、**p<0.01表示采用Mann-Whitney U检验，在每个时间点与接受过系统治疗患者的对应值存在显著差异。 经结合Bonferroni校正的Friedman检验显示，两组在以下时间段的指标与基线值存在显著差异： 1. IgE：未接受过系统治疗组为第12~48周（p<0.01），接受过系统治疗组为第4周（p<0.05）及第12~48周（p<0.01）。 2. TARC：两组均为第4~48周（p<0.01）。 3. LDH：未接受过系统治疗组为第24周（p<0.05）及第36、48周（p<0.01），接受过系统治疗组为第4、12、24周（p<0.01）、第36周（p<0.05）及第48周（p<0.01）。 4. TEC：两组均无显著差异。